Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Seelos Therapeutics, Inc. (SEEL)

0.6912   -0.001 (-0.12%) 03-31 16:00
Open: 0.7 Pre. Close: 0.692
High: 0.7147 Low: 0.67
Volume: 303,195 Market Cap: 75(M)

Technical analysis

as of: 2023-03-31 4:22:00 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.84     One year: 0.94
Support: Support1: 0.57    Support2: 0.48
Resistance: Resistance1: 0.72    Resistance2: 0.81
Pivot: 0.68
Moving Average: MA(5): 0.69     MA(20): 0.67
MA(100): 0.81     MA(250): 0.84
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 72.2     %D(3): 74.4
RSI: RSI(14): 48.8
52-week: High: 1.51  Low: 0.47
Average Vol(K): 3-Month: 566 (K)  10-Days: 495 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SEEL ] has closed below upper band by 41.1%. Bollinger Bands are 71.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.72 - 0.72 0.72 - 0.72
Low: 0.66 - 0.67 0.67 - 0.67
Close: 0.68 - 0.69 0.69 - 0.7

Company Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Headline News

Thu, 30 Mar 2023
Should You Buy Seelos Therapeutics Inc (SEEL) Stock on Thursday? - InvestorsObserver

Fri, 24 Mar 2023
Meta Platforms To Rally Over 32%? Here Are 10 Other Analyst ... - Investing.com UK

Wed, 15 Mar 2023
What is the Market's View on Seelos Therapeutics Inc (SEEL ... - InvestorsObserver

Tue, 14 Mar 2023
SEELOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Sun, 12 Mar 2023
10 Best Psychedelic Stocks to Buy According to Hedge Funds - Yahoo Finance

Wed, 08 Mar 2023
7 Best Psychedelic Stocks to Watch in 2023 - WTOP

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 107 (M)
Shares Float 104 (M)
% Held by Insiders 2.9 (%)
% Held by Institutions 28.3 (%)
Shares Short 5,730 (K)
Shares Short P.Month 5,920 (K)

Stock Financials

EPS -0.63
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -82.4
Return on Equity (ttm) -203.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -67 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -1.11
PEG Ratio 0
Price to Book value 2.16
Price to Sales 0
Price to Cash Flow -1.11

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-01-23
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.